医学
临床试验
钙调神经磷酸酶
重症监护医学
美罗华
抗代谢物
造血干细胞移植
环磷酰胺
移植物抗宿主病
挽救疗法
鲁索利替尼
移植
内科学
免疫学
甲氨蝶呤
化疗
淋巴瘤
骨髓
骨髓纤维化
作者
Omer Jamy,Robert Zeiser,Yi-Bin Chen
出处
期刊:Blood
[American Society of Hematology]
日期:2023-09-21
卷期号:142 (12): 1037-1046
被引量:3
标识
DOI:10.1182/blood.2023020073
摘要
Abstract Acute graft-versus-host disease (aGVHD) is a major life-threatening complication after allogeneic hematopoietic cell transplant. Traditional standard prophylaxis for aGVHD has included a calcineurin inhibitor plus an antimetabolite, whereas treatment has relied mainly on corticosteroids, followed by multiple nonstandard second-line options. In the past decade, this basic framework has been reshaped by approval of antithymocyte globulin products, the emergence of posttransplant cyclophosphamide, and recent pivotal trials studying abatacept and vedolizumab for GVHD prophylaxis, whereas ruxolitinib was approved for corticosteroid-refractory aGVHD treatment. Because of this progress, routine acute GVHD prophylaxis and treatment practices are starting to shift, and results of ongoing trials are eagerly awaited. Here, we review recent developments in aGVHD prevention and therapy, along with ongoing and future planned clinical trials in this space, outlining what future goals should be and the limitations of current clinical trial designs and end points.
科研通智能强力驱动
Strongly Powered by AbleSci AI